EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Network pharmacology and molecular docking of cucurbitane-type triterpenoids from Momordica charantia against psoriasis-associated targets

Ahmad Bayu Satriawan, Sarmoko, Tantri Liris Nareswari, Nisa Yulianti Suprahman, Muh Fajar Fauzi, I Gede Raditya Purwanata

Pharmacy Reports · 20.06.2026 · 6 (3) · 127

DOI: 10.51511/pr.127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy Reports, online erschienen am 20.06.2026. Verfasst von Ahmad Bayu Satriawan und 5 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by keratinocyte hyperproliferation, persistent inflammation, dysregulated apoptosis, and tissue remodeling. Momordica charantia has attracted attention as a potential anti-psoriatic herbal candidate; however, the molecular basis of its bioactive metabolites remains insufficiently understood. This study investigated the anti-psoriatic potential of cucurbitane-type triterpenoids from M. charantia using integrated network pharmacology and molecular docking. Of 192 secondary metabolites, 50 passed pharmacokinetic and toxicity screening, yielding 347 predicted human targets, of which 159 overlapped with 3,383 psoriasis-associated genes. Key hub genes identified by protein-protein interaction and topological analyses included AKT1, TNF, EGFR, STAT3, IL1B, CASP3, MMP9, HIF1A, and ESR1, with enriched biological processes related to oxidative stress, lipid and hormonal responses, and intracellular receptor signaling. Molecular docking of five cucurbitane-type triterpenoids against four validated hub proteins demonstrated consistently favorable predicted binding affinities for AKT1 via its allosteric pocket, as well as for EGFR and IL1B. Karavilagenin A showed the most favorable binding energy against AKT1, momordicin I against EGFR and IL1B, and cucurbitacin B demonstrated favorable profiles across multiple targets. These findings suggest that M. charantia may influence psoriasis-related biology through multi-target mechanisms, providing a basis for further experimental validation.

Zitieren

APA

Satriawan, A. B., Sarmoko, Nareswari, T. L., Suprahman, N. Y., Fauzi, M. F., & Purwanata, I. G. R. (2026). Network pharmacology and molecular docking of cucurbitane-type triterpenoids from Momordica charantia against psoriasis-associated targets. Pharmacy Reports, 6(3), 127. https://doi.org/10.51511/pr.127

Vancouver

Satriawan AB, Sarmoko, Nareswari TL, Suprahman NY, Fauzi MF, Purwanata IGR. Network pharmacology and molecular docking of cucurbitane-type triterpenoids from Momordica charantia against psoriasis-associated targets. Pharmacy Reports. 2026;6(3):127. doi:10.51511/pr.127

BibTeX
@article{Satriawan2026,
  author = {Satriawan, Ahmad Bayu and Sarmoko and Nareswari, Tantri Liris and Suprahman, Nisa Yulianti and Fauzi, Muh Fajar and Purwanata, I Gede Raditya},
  title = {Network pharmacology and molecular docking of cucurbitane-type triterpenoids from Momordica charantia against psoriasis-associated targets},
  journal = {Pharmacy Reports},
  year = {2026},
  volume = {6},
  number = {3},
  pages = {127},
  doi = {10.51511/pr.127}
}
Kostenlos starten →